Prior authorization kits may improve treatment access for minorities

Specifically, the kits provide prior authorization information for PCSK9 inhibitors to treat lipid disorders, direct oral anticoagulants for stroke prevention and angiotensin receptor-neprilysin inhibitors for heart failure treatment. Those three categories of drugs were commonly pinpointed as being “always” or “often” denied by insurance companies in surveys of providers.